Publications

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer

Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Mathews D, Gao A, Garant A, Arriaga YE, Bowman I, Chung J-S, Wang J, Ariizumi K, Ahn C, Timmerman R, Courtney K. Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer. Biomedicines, 2022 Jun 15;10(6):1419. doi: 10.3390/biomedicines10061419.

Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients

Kobayashi M, Chung J-S, Beg M, Arriaga Y, Verma U, Courtney K, Mansour JC, Haley B, Khan SA, Horiuchi Y, Ramani V, Harker D, Gopal P, Araghizadeh F, Cruz PD Jr., Ariizumi K. Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients. Clin Cancer Res. 2019. 25:828-838. PMID: 30049749.